Axsome Therapeutics, Inc. (AXSM) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Net income in fiscal 2025 was -$183M, a net margin of -28.7%; the best year in this period was 2016 with -$27M.
Over the twelve months to September 30, 2026, revenue was $865M and net income -$157M.
Free cash flow was -$94M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 160% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $865M | $638M | $386M | $271M | $50M | — | — | — | — | — | — |
| Gross profit | — | — | — | — | $45M | — | — | — | — | — | — |
| Operating income | -$151M | -$167M | -$281M | -$232M | -$180M | -$125M | -$99M | -$67M | -$33M | -$27M | -$28M |
| Net income | -$157M | -$183M | -$287M | -$239M | -$187M | -$130M | -$103M | -$68M | -$31M | -$29M | -$27M |
| EPS (diluted) | $-3.05 | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.47 | $-2.77 | $-2.01 | $-1.15 | $-1.27 | $-1.42 |
| R&D | $198M | $183M | $187M | $98M | $58M | $58M | $70M | $54M | $23M | $20M | $21M |
| Revenue growth | — | +65.5% | +42.5% | +440.8% | — | — | — | — | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$82M | -$93M | -$128M | -$145M | -$117M | -$108M | -$78M | -$46M | -$30M | -$26M | -$21M |
| Capital spending | -$839000 | -$480000 | -$270000 | -$582000 | -$702000 | -$308000 | -$45891 | -$16121 | -$32696 | -$9898 | -$104561 |
| Free cash flow | -$83M | -$94M | -$129M | -$146M | -$117M | -$109M | -$79M | -$46M | -$30M | -$26M | -$21M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $100M | $94M | $85M | $63M | $38M | $21M | $15M | $6M | $2M | $2M | $2M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $323M | $315M | $386M | $201M | $86M | $184M | $220M | — | — | — |
| Debt | — | $211M | $189M | $188M | $95M | $51M | $52M | $20M | $7M | $10M | $10M |
| Equity | — | $88M | $57M | $191M | $110M | $16M | $114M | $179M | $937921 | $17M | $22M |
| Total assets | — | $690M | $568M | $588M | $331M | $88M | $186M | $221M | $15M | $36M | $38M |
| Shares (diluted) | 52M | 50M | 48M | 45M | 41M | 38M | 37M | 34M | 27M | 23M | 19M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | 89.6% | — | — | — | — | — | — |
| Operating margin | -17.5% | -26.1% | -72.7% | -85.7% | -359.3% | — | — | — | — | — | — |
| Net margin | -18.2% | -28.7% | -74.5% | -88.4% | -374.0% | — | — | — | — | — | — |
| FCF margin | -9.5% | -14.7% | -33.4% | -53.8% | -234.2% | — | — | — | — | — | — |
| ROIC | — | -55.5% | -90.2% | -48.3% | -87.7% | -188.2% | -47.3% | -26.7% | -330.6% | -80.5% | -69.5% |
| ROE | — | -207.5% | -503.8% | -125.3% | -170.8% | -834.3% | -90.4% | -38.2% | -3301.5% | -173.1% | -126.1% |
Frequently asked questions
What is Axsome Therapeutics’s annual revenue?
$638M in fiscal 2025 and $865M over the twelve months to September 30, 2026.
How much profit does Axsome Therapeutics make?
Net income was -$183M in fiscal 2025 (net margin -28.7%).
Is Axsome Therapeutics’s revenue growing?
Yes: revenue rose 65.5% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.